✦ LIBER ✦

A rare point mutation in the Ras oncogene in hepatocellular carcinoma

✍ Scribed by Taketomi, Akinobu; Shirabe, Ken; Muto, Jun; Yoshiya, Shohei; Motomura, Takashi; Mano, Yohei; Ikegami, Tohru; Yoshizumi, Tomoharu; Sugio, Kenji; Maehara, Yoshihiko

Book ID: 120479024
Publisher: Springer
Year: 2012
Tongue: English
Weight: 361 KB
Volume: 43
Category: Article
ISSN: 1436-2813
DOI: 10.1007/s00595-012-0462-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infrequent point mutations in codons 12

Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas

✍ Challen, C.; Guo, K.; Collier, J.D.; Cavanagh, D.; Bassendine, M.F. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 668 KB

H-ras oncogene point mutations in arthri

H-ras oncogene point mutations in arthritic synovium

✍ Anne Roivainen; Jari Jalava; Laura Pirilä; Tuomas Yli-Jama; Hannu Tiusanen; Paav 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 868 KB

Ras oncogene point mutation: An infreque

Ras oncogene point mutation: An infrequent event in bronchioloalveolar cancer

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 312 KB

POINT MUTATION IN c-HA-ras ONCOGENE IN N

POINT MUTATION IN c-HA-ras ONCOGENE IN NORMAL AND ABNORMAL CELLS

✍ Nag, Abhijit; Jones, JeffreyA.; Smith, RoyG. 📂 Article 📅 1989 🏛 The Lancet 🌐 English ⚖ 480 KB

Amplification and point mutation of the

Amplification and point mutation of the Ha-ras oncogene in lung cancer

✍ Chen, Jia-kun; He, Ling; Wu, Zhong-liang; Du, Ying-xiu 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Ras oncogene point mutations in bladder

Ras oncogene point mutations in bladder cancer resistant to cisplatin

✍ Wood, D. P. ;Anderson, A. E. ;Fair, R. ;Chaganti, R. S. K. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 486 KB

Bladder tumors respond to cisplatin-based chemotherapy in 68% of cases, but only 30% will have a durable response. Recent studies have suggested that ras point mutations may produce cisplatin drug resistance in cell lines. To determine the role of ras point mutations in human tumors resistant to cis